Jenscare Scientific (9877) Fundamentals 2026 — Revenue Analysis | SniperIQ
Jenscare Scientific (9877) is a CN-listed Healthcare company in Medical - Specialties with a market capitalization of HK
Jenscare Scientific (9877) has a market capitalization of approximately HK
Jenscare Scientific's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Jenscare Scientific runs a net profit margin of -223.7%, a gross margin of 80.5%, and an operating margin of -191.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Jenscare Scientific reported revenue of ¥88M for fiscal year 2025, with net income of -¥264M and earnings per share (EPS) of -0.64. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Jenscare Scientific does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Jenscare Scientific carries a debt-to-equity ratio of 0.06x and a current ratio of 5.86x, with a market beta of 0.65. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Jenscare Scientific (9877) the key facts are: market cap HK
Get Jenscare Scientific's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.